Kane Biotech Announces Third Quarter 2025 Financial Results
Kane Biotech reported total revenue of $8,499 for Q3 2025, significantly down from $1,282,698 in Q3 2024, primarily due to termination of animal health manufacturing and US distribution agreements in early 2025.
Gross loss for Q3 2025 was $(5,128) compared to a gross profit of $558,754 in Q3 2024.
Operating expenses for Q3 2025 were $538,306, reduced from $1,170,064 in Q3 2024, due to lower staff and business development costs.
Net loss for Q3 2025 was $(607,345), slightly improved from a net loss of $(678,636) in Q3 2024.
Cash on hand as of September 30, 2025 was $939,062.
The company is actively pursuing a three-pillar strategy focused on advancing their wound care product revyve in the U.S. through clinical case series, conference presentations, and rebuilding distributor and sales agent networks.
Kane Biotech completed FDA 510(k) clearance submission for revyve Antimicrobial Wound Cleanser and is advancing distributor discussions in the U.S.
The clinical case series for revyve has exceeded enrollment targets and is generating compelling data presented at industry conferences, supporting efforts to rebuild U.S. distribution and expand into Canada.